A recent press release reported that the phase III BR31 trial (NCT02273375) testing adjuvant durvalumab in patients with resected stage IB-IIIA NSCLC with PD-L1 expression ≥25% did not lead to statistically significant improvement in DFS compared with placebo. The gene discussed is CD274; the disease is non-small cell lung carcinoma.